WallStSmart

Merck & Company Inc (MRK)vsSpok Holdings Inc (SPOK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 46433% more annual revenue ($65.01B vs $139.71M). MRK leads profitability with a 28.1% profit margin vs 11.4%. MRK trades at a lower P/E of 15.2x. MRK earns a higher WallStSmart Score of 59/100 (C).

MRK

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 9.5Value: 4.7Quality: 4.8
Piotroski: 3/9

SPOK

Hold

43

out of 100

Grade: D

Growth: 2.7Profit: 6.0Value: 7.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKOvervalued (-13.2%)

Margin of Safety

-13.2%

Fair Value

$96.48

Current Price

$109.18

$12.70 premium

UndervaluedFair: $96.48Overvalued
SPOKUndervalued (+53.3%)

Margin of Safety

+53.3%

Fair Value

$28.91

Current Price

$11.05

$17.86 discount

UndervaluedFair: $28.91Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK6 strengths · Avg: 9.2/10
Market CapQuality
$274.03B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
36.9%10/10

Every $100 of equity generates 37 in profit

Operating MarginProfitability
32.8%10/10

Strong operational efficiency at 32.8%

Profit MarginProfitability
28.1%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

SPOK2 strengths · Avg: 8.0/10
P/E RatioValuation
15.3x8/10

Attractively priced relative to earnings

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Areas to Watch

MRK3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.362/10

Expensive relative to growth rate

EPS GrowthGrowth
-19.3%2/10

Earnings declined 19.3%

SPOK3 concerns · Avg: 2.3/10
Market CapQuality
$237.78M3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-0.1%2/10

Revenue declined 0.1%

EPS GrowthGrowth
-27.2%2/10

Earnings declined 27.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.

Bull Case : SPOK

The strongest argument for SPOK centers on P/E Ratio, Price/Book.

Bear Case : MRK

The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.

Bear Case : SPOK

The primary concerns for SPOK are Market Cap, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

MRK profiles as a value stock while SPOK is a declining play — different risk/reward profiles.

SPOK carries more volatility with a beta of 0.47 — expect wider price swings.

MRK is growing revenue faster at 5.0% — sustainability is the question.

MRK generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (59/100 vs 43/100), backed by strong 28.1% margins. SPOK offers better value entry with a 53.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Spok Holdings Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Spok Holdings, Inc., through its subsidiary, Spok, Inc., provides healthcare communication solutions in the United States, Europe, Canada, Australia, Asia, and the Middle East. The company is headquartered in Springfield, Virginia.

Want to dig deeper into these stocks?